EGFR and urinary bladder cancer: The aim of this study is to investigate crosstalk between these two signalling axes as they share some common downstream signalling effectors and evaluate whether combination of PPARγ agonist and an EGFR inhibitor may overcome resistance to EGFR therapy in bladder cancer.